Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : WO533
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : proDERM Institute | Bremer Pharmacovigilance Service
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 10, 2020
Lead Product(s) : WO533
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : proDERM Institute | Bremer Pharmacovigilance Service
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : WO3970
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Therapeutics, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 12, 2019
Lead Product(s) : WO3970
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Therapeutics, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : WO3970
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 05, 2018
Lead Product(s) : WO3970
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : WO2085
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : proDERM Institute | Bremer Pharmacovigilance Service | GCP-Service International
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 07, 2017
Lead Product(s) : WO2085
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : proDERM Institute | Bremer Pharmacovigilance Service | GCP-Service International
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : WO3979
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Nuvisan GmbH | FGK Clinical Research | Charles River Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 31, 2017
Lead Product(s) : WO3979
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Nuvisan GmbH | FGK Clinical Research | Charles River Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : WOL071-007
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 15, 2015
Lead Product(s) : WOL071-007
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable